Home News Covid-19

China vaccine's low efficacy due to high-risk group, says Sinovac CEO

Bloomberg
Bloomberg1/14/2021 09:52 AM GMT+08  • 2 min read
China vaccine's low efficacy due to high-risk group, says Sinovac CEO
Sinovac says the low efficacy rate of 50.38% from its final-stage trial in Brazil is due to participants being medical workers.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Chinese vaccine developer Sinovac Biotech Ltd. said that the low efficacy rate of 50.38% from its final-stage trial in Brazil is due to trial participants being medical workers facing a high risk of contracting Covid-19.

In contrast, western vaccines like that developed by Pfizer Inc. and BioNTech SE were tested among volunteers including people from the general population, some of whom were less exposed to the virus in their daily lives compared to medical workers.

The defence from Sinovac Chief Executive Officer Yin Weidong at a press briefing in Beijing on Jan 13 followed growing confusion as trials conducted in Brazil, Indonesia and Turkey released four different efficacy rates for the same vaccine.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now